The use of GLP1RAs, PPARγ agonists like pioglitazone, and dual PPARα/PPARδ agonists like elafibranor hold promise in influencing macrophage polarization, inflammatory pathways, and improving liver histology in NASH. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.